Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083495 | 0.98 | PNMT (0.61) | PNMTADRA2AMEN1KMT2AMAPT | |
| SCHEMBL1715396 | 0.94 | PNMT (0.61) | PNMTADRA2AMEN1KMT2AMAPT | |
| SCHEMBL30709850 | 0.90 | PNMT (0.65) | PNMTADRA2AMEN1KMT2AMAPT | |
| SCHEMBL9483063 | 0.90 | PNMT (0.65) | PNMTADRA2AMEN1KMT2AMAPT | |
| SCHEMBL467503 | 0.82 | PNMT (0.57) | PNMTADRA2AMEN1KMT2AMAPT | |
| SCHEMBL2246184 | 0.82 | PTPRC (0.50) | PNMTADRA2AMEN1KMT2AMAPT | |
| SCHEMBL3814176 | 0.82 | PTPRC (0.50) | PNMTADRA2AMEN1KMT2AMAPT | |
| SCHEMBL29119402 | 0.81 | LMNA (0.50) | PNMTADRA2ARAB9ALMNANPC1 | |
| SCHEMBL8899725 | 0.81 | ADRA2A (0.44) | PNMTADRA2AMEN1KMT2AMAPT | |
| SCHEMBL2061267 | 0.81 | PNMT (0.56) | PNMTADRA2AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450263-B2 | Benzo annulenes as antiviral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2019-10-22 | — | — | US | disclosed |
| US-8207160-B2 | Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010083465-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20090105224-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-1828125-B1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET SOC CIV (FR) | 2008-04-09 | — | — | EP | disclosed |
| EP-1828125-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105224-A1 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor | DRD3, DRD2, ADRB3 | PNMT 707/4885ADRA2A 45/4885MEN1 4526/4885 |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | SLC6A3, ADRB3, PRLHR | PNMT 292/4885ADRA2A 37/4885MEN1 4726/4885 |
| US-10450263-B2 | Benzo annulenes as antiviral agents | MAVS, ZC3HAV1, GABBR1 | PNMT 4103/4885ADRA2A 1552/4885MEN1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.